Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heiko Götte

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Statistics in Medicine|August 4, 2012
Sample size planning for survival prediction with focus on high-dimensional dataHeiko Götte, Isabella Zwiener
Biometrical Journal. Biometrische Zeitschrift|October 8, 2019
Adjustment for exploratory cut-off selection in randomized clinical trials with survival endpointHeiko Götte, Marietta Kirchner, Meinhard Kieser
Journal of Biopharmaceutical Statistics|June 13, 2025
Estimation of treatment effects in early phase randomized clinical trials involving multiple data sources for external controlHeiko Götte, Marietta Kirchner, Meinhard Kieser
Statistics in Medicine|February 20, 2009
Adaptive designs with correlated test statisticsHeiko Götte, Gerhard Hommel, Andreas Faldum
Journal of Biopharmaceutical Statistics|June 11, 2014
Improving Probabilities of Correct Interim Decision in Population Enrichment DesignsHeiko Götte, Margarita Donica, Giacomo Mordenti
Pharmaceutical Statistics|February 24, 2017
Probability of success for phase III after exploratory biomarker analysis in phase IIHeiko Götte, Marietta Kirchner, Martin Oliver Sailer
Statistics in Medicine|August 11, 2015
Utility-based optimization of phase II/III programsMarietta Kirchner, Meinhard Kieser, Heiko Götte, et al.
BMC Medical Research Methodology|October 10, 2020
Optimal designs for phase II/III drug development programs including methods for discounting of phase II resultsStella Erdmann, Marietta Kirchner, Heiko Götte, et al.
Pharmaceutical Statistics|April 28, 2018
Optimal planning of phase II/III programs for clinical trials with multiple endpointsMeinhard Kieser, Marietta Kirchner, Eva Dölger, et al.
Pharmaceutical Statistics|September 29, 2015
Sample size planning for phase II trials based on success probabilities for phase IIIHeiko Götte, Armin Schüler, Marietta Kirchner, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Statistics in Medicine|August 4, 2012
Sample size planning for survival prediction with focus on high-dimensional dataHeiko Götte, Isabella Zwiener
Biometrical Journal. Biometrische Zeitschrift|October 8, 2019
Adjustment for exploratory cut-off selection in randomized clinical trials with survival endpointHeiko Götte, Marietta Kirchner, Meinhard Kieser
Journal of Biopharmaceutical Statistics|June 13, 2025
Estimation of treatment effects in early phase randomized clinical trials involving multiple data sources for external controlHeiko Götte, Marietta Kirchner, Meinhard Kieser
Statistics in Medicine|February 20, 2009
Adaptive designs with correlated test statisticsHeiko Götte, Gerhard Hommel, Andreas Faldum
Journal of Biopharmaceutical Statistics|June 11, 2014
Improving Probabilities of Correct Interim Decision in Population Enrichment DesignsHeiko Götte, Margarita Donica, Giacomo Mordenti
Pharmaceutical Statistics|February 24, 2017
Probability of success for phase III after exploratory biomarker analysis in phase IIHeiko Götte, Marietta Kirchner, Martin Oliver Sailer
Statistics in Medicine|August 11, 2015
Utility-based optimization of phase II/III programsMarietta Kirchner, Meinhard Kieser, Heiko Götte, et al.
BMC Medical Research Methodology|October 10, 2020
Optimal designs for phase II/III drug development programs including methods for discounting of phase II resultsStella Erdmann, Marietta Kirchner, Heiko Götte, et al.
Pharmaceutical Statistics|April 28, 2018
Optimal planning of phase II/III programs for clinical trials with multiple endpointsMeinhard Kieser, Marietta Kirchner, Eva Dölger, et al.
Pharmaceutical Statistics|September 29, 2015
Sample size planning for phase II trials based on success probabilities for phase IIIHeiko Götte, Armin Schüler, Marietta Kirchner, et al.
Pageof 3